Analysts Weigh in on Cytori Therapeutics (CYTX)

Cytori Therapeutics, Inc. (CYTX) average trading volume of 1,602,305 during the past month is 53.77% above its average volume over the past year, indicating that investors have been more active than usual in the stock in recent times. Wall Street analysts covering the stock are projecting that the stock will reach $2.08 within the next 52-weeks.

On the other hand the company has Relative Strength Index (RSI 14) of 56.19 along with Average True Range (ATR 14) of 0.05, Consequently Cytori Therapeutics (NASDAQ:CYTX)'s weekly and monthly volatility is 34.58%, 16.92% respectively.

In terms of Buy, Sell or Hold recommendations, Cytori Therapeutics (NASDAQ:CYTX) has analysts' mean recommendation of 2.3.

The stock now shows its YTD (Year to Date) performance of 12.7 percent, whereas its Weekly performance stands at 20.15%. Through this figure traders can analyze that CYTX show whether or not a stock now most active and standing in buying side or sell side. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.02. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. According to the most recent data, Cytori Therapeutics, Inc. has a 52-week high of $2.13 and a 52-week low of $0.22. The share price has moved forward from its 20 days moving average, trading at a distance of 0.85% and stays 4.31% away from its 50 days moving average.

Analysts set a 12-month price target of $2.08 a share. The firm had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million.

Da Trump ultimatum alla UE: rivedere subito l'accordo con l'Iran
Il presidente ha anche annullato una visita in Gran Bretagna il mese prossimo per inaugurare la nuova ambasciata Usa a Londra . Nei giorni scorsi la stampa britannica aveva sostenuto che la visita sarebbe stata segnata dalle proteste.

Analysts are expecting average earnings estimates of $-0.06 for the current quarter based on the opinion of 3 analysts, relating to high earnings per share estimates of $-0.04 and low estimates of $-0.07, however Cytori Therapeutics (NASDAQ:CYTX) reported $-0.24 earnings per share for the same quarter past year. By looking at the Volatility of the company, Week Volatility is at 5.20%, whereas Month Volatility stands at 5.98%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0.47%. The company has a market capitalization of $11.59, a price-to-earnings ratio of -0.40 and a beta of 3.21.

Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Bank Sa Swissquote sold 100,000 shares of the company's stock in a transaction dated Tuesday, January 9th. The stock hit its 52-week high on 02/15/17, and 52-week low on 12/15/17.

Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Thursday, November 9th.

According to analysts Cytori Therapeutics (NASDAQ:CYTX)'s minimum EPS for the current quarter is at $-0.07 and can go high up to $-0.04. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E.

Latest News